Thermo Fisher leads fetal bovine serum market as animal-free alternatives gain ground

Thermo Fisher Scientific led global fetal bovine serum sales in 2024 with a 6% share, according to a new market report from The Business Research Company. The report says the market is fairly concentrated, while animal-component-free alternatives are starting to reshape competition in cell culture and cultivated meat.

Why it matters: - Fetal bovine serum remains a core input for cell culture, biopharmaceutical research and vaccine development. - The market is still concentrated, but competition is being pressured by animal-component-free alternatives. - Suppliers that can improve consistency, traceability and ethical sourcing are better positioned as buyers face tighter quality and regulatory expectations.

What happened: - The Business Research Company published a 2026 fetal bovine serum market report covering market size, trends and forecasts for 2026-2035. - Thermo Fisher Scientific led global sales in 2024 with a 6% market share. - The report says the top 10 players accounted for 30% of total market revenue in 2024. - The report lists Thermo Fisher Scientific, Merck KGaA, Cytiva, Sartorius AG, Corning Incorporated, Gemini Bio-Products, VWR International, GenClone Inc., Access Biologicals LLC and PAA Laboratories as leading companies.

The details: - Thermo Fisher Scientific’s biosciences and cell culture division sells cell culture reagents, fetal bovine serum products and bioprocessing solutions. - The company’s offerings support biopharmaceutical research, vaccine development and cell-based research applications. - The report says the market is fairly concentrated because of moderate technological and regulatory barriers. - Those barriers include stringent quality control, ethical sourcing standards, raw material supply variability and the need for consistent cell culture performance. - The report identifies major raw material suppliers including Thermo Fisher Scientific, Merck KGaA, Lonza Group, Sartorius, GE Healthcare Life Sciences, Danaher, Bio-Rad, Corning, Cytiva Life Sciences, HiMedia Laboratories and PAN-Biotech. - Major wholesalers and distributors include Avantor, Fisher Scientific International, McKesson, Cardinal Health, Medline Industries, VWR International Distribution Services, Henry Schein, Owens & Minor and Patterson Companies. - Major end users include Pfizer, Novartis, Roche, Sanofi, AstraZeneca, GSK, Merck & Co., Johnson & Johnson, Bayer, Amgen, Bristol Myers Squibb, Eli Lilly, Takeda, Boehringer Ingelheim, Gilead, Regeneron, AbbVie, Genentech, Moderna, Vertex, Charles River Laboratories, WuXi AppTec, Lonza Biologics, Eurofins Scientific and Catalent. - The report says leading companies are investing in fetal bovine serum production, purification systems, bioprocessing infrastructure and AI-based quality systems. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspot infographics and updated graphics and tables. - Readers can request a free sample of the report or access the detailed market report.

Between the lines: - The strongest near-term threat to fetal bovine serum demand is not another serum supplier, but animal-component-free media. - Multus Biotechnology launched proliferum B in December 2024 as an animal-component-free cell culture solution for cultivated meat production. - The product is designed to support robust cell growth, reduce reliance on animal-derived inputs and lower cost and ethical barriers in cultivated meat manufacturing. - The competitive edge in this market is shifting toward process control, reproducibility and supply-chain reliability rather than price alone.

What's next: - The report expects strategic collaborations, product innovation and regional expansion to strengthen leading companies' positions. - Demand for high-quality cell culture reagents, biopharmaceutical inputs and vaccine development materials is expected to support continued market activity. - Animal-free alternatives are likely to keep expanding in research and cultivated meat applications, adding pressure on traditional fetal bovine serum suppliers.

The bottom line: - Thermo Fisher is leading a concentrated market, but the bigger story is a gradual shift toward higher standards, tighter compliance and alternative cell culture inputs.